IQV Stock Analysis: Buy, Sell, or Hold?
IQV - IQVIA Holdings Inc.
$174.06
1.66 (0.96%)
▲
5d:
+2.75%
30d:
-2.15%
90d:
-22.78%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 05, 2026
Smart Money Accumulation
IQV is down 8.7% this week, but smart money is accumulating calls. Top strike: $210 2026-05-15 with 1,239 OI. Call ratio: 78% View Scanner →
Strength: 7.2/10
Get Alerted When IQV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: IQV appears deeply undervalued. Market expects -6.8% annual earnings decline despite 24% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: IQV appears deeply undervalued. Market expects -6.8% annual earnings decline despite 24% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$304.11
Based on 7.4% avg growth
INTRINSIC VALUE TODAY
$188.83
7.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IQV is currently trading at $174.06, which is considered oversold relative to its 30-day fair value range of $163.96 to $174.08. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.2) compared to its historical average (15.1). Remarkably, the market is currently pricing in an annual earnings decline of 6.8% over the next few years. This pessimistic expectation contrasts with the company's recent 23.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IQV is in a strong uptrend. The price is approaching resistance at $174.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IQV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $236.00 (+36.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IQV is in a strong uptrend. The price is approaching resistance at $174.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IQV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $236.00 (+36.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$163.96 -
$174.08
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 36.9% below Wall St target ($236.00)
Fair Price Analysis
30-Day Fair Range
$163.96 -
$174.08
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$162.36
Resistance Level
$174.27
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.24
Wall Street Target
$236.00
(+36.9%)
Revenue Growth (YoY)
10.3%
Earnings Growth (YoY)
23.6%
Profit Margin
8.3%
Valuation Discount vs History
-6.8% cheaper
PE vs Historical
12.2 vs 15.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.8%
(market-implied from PE analysis)
1-Year Target
$160.68
(-7%)
2-Year Target
$149.75
(-13%)
3-Year Target
$139.57
(-19%)
3-Yr Target (if PE normalizes)
(PE: 12→15)
$172.11
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 10.9%)
$428.89
(+149%)
Base:
(SPY PE: 12.2, Growth: 10.9%)
$234.98
(+36%)
Bear:
(PE: 10.4, Growth: 10.9%)
$199.73
(+16%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 21.18 | Current EPS (TTM): $7.84
Bull Case
$327.67
(+96%)
Analyst growth 79.4%, PE expands to 23.3
Base Case
$297.88
(+78%)
Market implied 79.4%, PE stable at 21.2
Bear Case
$112.93
(-32%)
Severe decline -20.0%, PE contracts to 18.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.2 to 15.1
Stabilization Target:
$212.60
(+23.3%)
PE Expansion Potential:
+23.3%
Share & Embed Analysis
Last updated: April 02, 2026 11:06 AM ET
Data refreshes hourly during market hours. Next update: 12:05 PM
Data refreshes hourly during market hours. Next update: 12:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IQV showing a specific setup today?
Insider Activity (6 Months)
1
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-02-24
Ro Khanna
SELL
2026-01-29
Markwayne Mullin
BUY
2025-12-29
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$664 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$265 | 66 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$133 | 62 BUY |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 66 BUY |
Advanced IQV Option Strategies
Professional options setups generated by AI based on today's IQV price and gamma walls.
